“Generic drug-making is a fast-track business”: Sandoz trademark head reveals approach to IP management

In a wide-ranging interview, INTA’s president-elect and global head of trademarks for Sandoz, David Lossignol, talks about the challenges of managing pharmaceutical brand rights and the growing threat of IP restrictions.